Lack of association between vigabatrin and impaired cognition

J Int Med Res. 1997 Sep-Oct;25(5):296-301. doi: 10.1177/030006059702500507.

Abstract

Of 14 patients with a history of partial epilepsy who received vigabatrin 2 g daily for 6 months, eight were newly diagnosed and received vigabatrin as monotherapy, while the remaining six received vigabatrin in addition to pre-existing treatment with phenobarbitone. Neurophysiological and neuropsychological evaluations, done before and after the therapeutic period, included the Luria-Nebraska neuropsychological battery (LNNB), electroencephalograms (EEGs) and evoked potentials. The results for each item of the test battery at baseline were compared with those after 6 months' treatment. There were no statistically significant differences on the functional scales of the LNNB, the EEG or the evoked potentials. There was a significant improvement (P = 0.01) in the LNNB topographic scales for the right frontal lobe and the motor-sensory area following treatment. These results indicate that vigabatrin has no detrimental effects on cognitive function and may improve function.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use*
  • Cognition Disorders / chemically induced*
  • Disorders of Excessive Somnolence / etiology
  • Electroencephalography
  • Epilepsies, Partial / drug therapy
  • Epilepsies, Partial / psychology
  • Evoked Potentials, Auditory, Brain Stem / drug effects
  • Female
  • Humans
  • Luria-Nebraska Neuropsychological Battery
  • Male
  • Seizures / complications
  • Vigabatrin
  • gamma-Aminobutyric Acid / adverse effects
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • Anticonvulsants
  • gamma-Aminobutyric Acid
  • Vigabatrin